Posted in | News | Nanobusiness

Shrink Nanotechnologies Forms New Subsidiary Named Shrink Solar

Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB:INKND) (OTCBB:INKN), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today the formation of a new wholly owned subsidiary called Shrink Solar LLC, which is focused on commercializing its solar technologies.

Using the Company’s breakthrough nano-structured solar film designs, Shrink’s unique solar concentrator designs, which will now be held in Shrink’s new wholly owned “Shrink Solar LLC” operating unit, will soon enable solar consumers to add “energy-producing abilities” to products already in production, from rooftop applications to windows and beyond. Imagine a window that produces power. Imagine a traditional silicon rooftop solar array that was made efficient enough, so much so, that it made real economic sense to invest in a solar system in the first place.

“Shrink Solar’s goal is to transform the $37 billion solar energy production market worldwide by designing and selling our solar concentrators as a low-cost performance enhancing add-on device, to create more wattage per square meter, for existing mono- and poly-crystalline solar cell arrays,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc. “Whereas silicon is only able to absorb a very narrow band of the available light produced from the sun, Shrink’s ‘tuned’ nano-crystal solar concentrator technology – which is non-optical – in other words it does not rely on mirrors, a lens or a tracking device – gathers the part of the light spectrum that silicon is unable to absorb – and then it converts that energy spectrum into a usable form (a re-emission) which become usable power.”

Baum added, “Many months ago we formed a relationship with Inabata America, primarily to leverage Inabata’s vast development and marketing resources to assist us as we went from the idea stage to prototype and then eventually to market. Now that we have made significant progress, and we expect to soon discuss this progress in more detail, we are establishing additional industry relationships to assist us in bringing these true ‘next-generation’ solar energy systems to market.”

Using Shrink Solar’s patent-pending nanocrystal-based technology, Shrink’s technologies enhance silicon’s ability to absorb sunlight and convert it to electricity. Shrink’s non-optical systems are a first-in-class solar concentrator that can boost energy production from legacy silicon PV systems by optimizing the light for absorption by silicon. A newly formed Renewable Energy Team, comprising distinguished academic and industry collaborators, will provide dedicated management support.

Source: http://www.shrinknano.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Shrink Nanotechnologies. (2019, February 13). Shrink Nanotechnologies Forms New Subsidiary Named Shrink Solar. AZoNano. Retrieved on April 16, 2024 from https://www.azonano.com/news.aspx?newsID=17298.

  • MLA

    Shrink Nanotechnologies. "Shrink Nanotechnologies Forms New Subsidiary Named Shrink Solar". AZoNano. 16 April 2024. <https://www.azonano.com/news.aspx?newsID=17298>.

  • Chicago

    Shrink Nanotechnologies. "Shrink Nanotechnologies Forms New Subsidiary Named Shrink Solar". AZoNano. https://www.azonano.com/news.aspx?newsID=17298. (accessed April 16, 2024).

  • Harvard

    Shrink Nanotechnologies. 2019. Shrink Nanotechnologies Forms New Subsidiary Named Shrink Solar. AZoNano, viewed 16 April 2024, https://www.azonano.com/news.aspx?newsID=17298.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.